Evidence map›Paper›PMID 42573921›Full record

ArticleDrug safety2026

Optimising Pharmacovigilance Efficiency with MLIT (Machine Learning for Intelligent Triage): A Tool for Statistical Safety Alerts.

Luciano Ciccarelli, Olivia Mahaux, Christie Roshan, Ami Fofana, Anna Kawka, Emilia Occhipinti, Mariapia Possidente, Silvia Cenci, Jeffery L Painter, Andrew Bate

Abstract read
PubMed Publisher
In one paragraph

Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Luciano Ciccarelli *GSK, Siena, Italy. luciano.x.ciccarelli@gsk.com.ORCID http://orcid.org/0009-0004-5468-1021
Olivia Mahaux *GSK, Wavre, Belgium. olivia.x.mahaux@gsk.com.ORCID http://orcid.org/0000-0002-9361-3118
Christie RoshanGSK, London, UK.ORCID http://orcid.org/0009-0006-5670-2767
Ami FofanaGSK, Siena, Italy.ORCID http://orcid.org/0009-0007-3976-527X
Anna KawkaGSK, Warsaw, Poland.ORCID http://orcid.org/0009-0004-1331-9528
Emilia OcchipintiGSK, Siena, Italy.ORCID http://orcid.org/0009-0009-6621-5913
Mariapia PossidenteGSK, Siena, Italy.ORCID http://orcid.org/0009-0006-2784-1573
Silvia CenciGSK, Siena, Italy.ORCID http://orcid.org/0009-0002-4413-4468
Jeffery L PainterGSK, Durham, NC, USA.ORCID http://orcid.org/0000-0001-9651-9904

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimPharmacovigilance is essential to ensuring patient safety by enabling timely identification of adverse reactions in increasingly complex and voluminous data. Routine quantitative signal detection methods generate statistical alerts for product-event pairs based on predefined criteria; however, most alerts do not warrant further investigation, creating inefficiencies and significant time demands for pharmacovigilance teams. Manual triage of these alerts is often resource-intensive, prone to variability, and challenging to audit, highlighting the need for more reliable, transparent and efficient triage strategies. This study aimed to design, develop and prospectively evaluate an explainable Machine Learning for Intelligent Triage (MLIT) tool to assist pharmacovigilance teams in reviewing statistical alerts for vaccine and drug portfolios. The objective was to enhance signal detection performance without increasing the risk of missing signals, improving operational efficiency and maintaining decision traceability and regulatory compliance.

methodsAlert and individual case safety report data were retrieved from the company's safety and signal management databases. Feature selection was guided by prior experience with a published case completeness tool, called Clinical Utility Score for Prioritisation (CUSP), and expert input. Of several ML methods explored, eXtreme Gradient Boosting (XGBoost) emerged as the optimal algorithm, with models trained and tested using a 75/25 split dataset. Iterative model refinement was conducted using Shapley Additive Explanations analyses to ensure explainability and alignment with safety reviewers' decision-making processes. Refined models underwent prospective validation in two four-month prospective validation studies, covering over 20 products across vaccine and drug portfolios. The prospective validations assessed concordance between model predictions and reviewers' decision under real-world conditions, as well as estimated time savings.

resultsThe vaccine model demonstrated robust predictive performance, achieving a weighted-average F1 score of 0.81 and an accuracy of 0.79. In the prospective validation phase, 92% of vaccine alerts were closed in alignment with the model's top-ranked prediction, while 98% were closed within the top 3 predictions. The MLIT tool also identified inconsistencies and human errors in manual triage, highlighting its potential role as a quality-control mechanism. Safety reviewers reported a 24% reduction in time spent on triage activities, and explainability analyses confirmed that the model's decision-making was conceptually aligned with safety reviewers' logic. Comparable results were observed for the drug portfolio.

conclusionThis study highlights the potential of ML-based tools to improve pharmacovigilance by enhancing signal detection performance, reducing the likelihood of missed signals, while increasing operational efficiency, and strengthening reproducibility and transparency. While MLIT demonstrated high concordance with expert decisions and provided meaningful time savings, human oversight remains essential, especially for low-confidence predictions. Ongoing refinement and user engagement will be critical for broader implementation and further automation, marking a significant step forward in ensuring safer and more efficient drug safety surveillance.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.